ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents

Cancer Discovery

Volumn 4, Issue 10, 2014, Pages 1198-1213

  Agnihotri, Sameer ^a   Burrell, Kelly ^a   Buczkowicz, Pawel ^a   Remke, Marc ^a   Golbourn, Brian ^a   Chornenkyy, Yevgen ^a   Gajadhar, Aaron ^b   Fernandez, Nestor A ^a   Clarke, Ian D ^a   Barszczyk, Mark S ^a   Pajovic, Sanja ^a   Ternamian, Christian ^a   Head, Renee ^a   Sabha, Nesrin ^a   Sobol, Robert W ^c,d,e   Taylor, Michael D ^a   Rutka, James T ^a   Jones, Chris ^f   Dirks, Peter B ^a   Zadeh, Gelareh ^a,g   Hawkins, Cynthia ^a   more..

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLPURINE DNA GLYCOSYLASE; ALKYLATING AGENT; ATM PROTEIN; DNA GLYCOSYLTRANSFERASE; METHOXYAMINE; SMALL INTERFERING RNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG; DACARBAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; EXCISION REPAIR; GENE DOSAGE; GENE EXPRESSION; GENE ONTOLOGY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PROTEIN PHOSPHORYLATION; SURVIVAL; TUMOR GROWTH; WESTERN BLOTTING; AGE; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; CLUSTER ANALYSIS; COPY NUMBER VARIATION; DISEASE MODEL; DNA REPAIR; DRUG RESISTANCE; DRUG SCREENING; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE;

AGE FACTORS; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL LINE, TUMOR; CLUSTER ANALYSIS; DACARBAZINE; DISEASE MODELS, ANIMAL; DNA COPY NUMBER VARIATIONS; DNA GLYCOSYLASES; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MODELS, BIOLOGICAL; PHOSPHORYLATION; RNA INTERFERENCE; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907549680     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0157     Document Type: Article

References (53)

1. Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer 2012; 12: 104-20.
2. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefi t from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
4. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994; 33: 9045-51.
5. Hang B, Singer B, Margison GP, Elder RH. Targeted deletion of alkylpurine-DNA-N-glycosylase in mice eliminates repair of 1, N6- ethenoadenine and hypoxanthine but not of 3,N4-ethenocytosine or 8-oxoguanine. Proc Natl Acad Sci U S A 1997; 94: 12869-74.
6. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine ? Nat Rev Neurol 2010; 6: 39-51.
7. Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro Oncol 2011; 13: 317-23.
8. Broniscer A, Chintagumpala M, Fouladi M, Krasin MJ, Kocak M, Bowers DC, et al. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol 2006; 76: 313-9.
9. Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffi ths PD, et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 2002; 20: 4684-91.
10. Ruggiero A, Cefalo G, Garre ML, Massimino M, Colosimo C, Attina G, et al. Phase II trial of temozolomide in children with recurrent high-grade glioma. J Neurooncol 2006; 77: 89-94.
11. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012; 482: 226-31.
12. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 defi ne distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012; 22: 425-37.
13. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, et al. K27M mutation in histone H3.3 defi nes clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 2012; 124: 439-47.
14. Fronza G, Gold B. The biological effects of N3-methyladenine. J Cell Biochem 2004; 91: 250-7.
15. Iyer P, Srinivasan A, Singh SK, Mascara GP, Zayitova S, Sidone B, et al. Synthesis and characterization of DNA minor groove binding alkylating agents. Chem Res Toxicol 2013; 26: 156-68.
16. Engelward BP, Dreslin A, Christensen J, Huszar D, Kurahara C, Samson L. Repair-defi cient 3-methyladenine DNA glycosylase homozygous mutant mouse cells have increased sensitivity to alkylation- induced chromosome damage and cell killing. EMBO J 1996; 15: 945-52.
17. Lau AY, Scharer OD, Samson L, Verdine GL, Ellenberger T. Crystal structure of a human alkylbase-DNA repair enzyme complexed toDNA: mechanisms for nucleotide fl ipping and base excision. Cell 1998; 95: 249-58.
18. Ye N, Holmquist GP, O’Connor TR. Heterogeneous repair of Nmethylpurines at the nucleotide level in normal human cells. J Mol Biol 1998; 284: 269-85.
19. Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, et al. Plasma and cerebrospinal fl uid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004; 10: 3728-36.
20. Baker SD, Wirth M, Statkevich P, Reidenberg P, Alton K, Sartorius SE, et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999; 5: 309-17.
21. Hammond LA, Eckardt JR, Baker SD, Eckhardt SG, Dugan M, Forral K, et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 1999; 17: 2604-13.
22. Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, et al. Integrated molecular genetic profi ling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 2010; 28: 3061-8.
23. Berchtold NC, Cribbs DH, Coleman PD, Rogers J, Head E, Kim R, et al. Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A 2008; 105: 15605-10.
24. Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, Huang A, et al. Whole-genome profi ling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 2010; 28: 1337-44.
25. Amanchy R, Periaswamy B, Mathivanan S, Reddy R, Tattikota SG, Pandey A. A curated compendium of phosphorylation motifs. Nat Biotechnol 2007; 25: 285-6.
26. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson M D, et al. Integrated genomic analysis identifi es clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
27. Gaspar N, Marshall L, Perryman L, Bax DA, Little SE, Viana-Pereira M, et al. MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res 2010; 70: 9243-52.
28. Gururangan S, Fisher MJ, Allen JC, Herndon JE, Quinn JA, Reardon DA, et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol 2007; 9: 161-8.
29. Nicholson HS, Krailo M, Ames MM, Seibel NL, Reid JM, Liu-Mares W, et al. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children’s Cancer Group. J Clin Oncol 1998; 16: 3037-43.
30. Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, et al. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest 2012; 122: 253-66.
31. Fishel ML, He Y, Smith ML, Kelley MR. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin Cancer Res 2007; 13: 260-7.
32. Ito M, Ohba S, Gaensler K, Ronen SM, Mukherjee J, Pieper RO. Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage. PloS One 2013; 8: e62351.
33. Tang JB, Svilar D, Trivedi RN, Wang XH, Goellner EM, Moore B, et al. N-methylpurine DNA glycosylase and DNA polymerase {beta} modulate BER inhibitor potentiation of glioma cells to temozolomide. Neuro Oncol 2011; 13: 471-86.
34. Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF, et al. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair. Cancer Res 2011; 71: 2308-17.
35. Agnihotri S, Wolf A, Munoz DM, Smith CJ, Gajadhar A, Restrepo A, et al. A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. J Exp Med 2011; 208: 689-702.
36. Rinne M, Caldwell D, Kelley MR. Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells. Mol Cancer Ther 2004; 3: 955-67.
37. Setser JW, Lingaraju GM, Davis CA, Samson L., Drennan CL. Searching for DNA lesions: structural evidence for lower- and higheraffi nity DNA binding conformations of human alkyladenine DNA glycosylase. Biochemistry 2012; 51: 382-90.
38. Hegde ML, Hazra TK, Mitra S. Functions of disordered regions in mammalian early base excision repair proteins. Cell Mol Life Sci 2010; 67: 3573-87.
39. Elder RH, Jansen JG, Weeks RJ, Willington MA, Deans B, Watson AJ, et al. Alkylpurine-DNA-N-glycosylase knockout mice show increased susceptibility to induction of mutations by methyl methanesulfonate. Mol Cell Biol 1998; 18: 5828-37.
40. Margison GP, O’Connor PJ. Biological implications of the instability of the N-glycosidic bone of 3-methyldeoxyadenosine in DNA. Biochim Biophys Acta 1973; 331: 349-56.
41. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specifi c killing of BRCA2-defi cient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-7.
42. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
43. Somyajit K, Basavaraju S, Scully R, Nagaraju G. ATM- and ATRmediated phosphorylation of XRCC3 regulates DNA double-strand break-induced checkpoint activation and repair. Mol Cell Biol 2013; 33: 1830-44.
44. Willis J, Patel Y, Lentz BL, Yan S. APE2 is required for ATR-Chk1 checkpoint activation in response to oxidative stress. Proc Natl Acad Sci U S A 2013; 110: 10592-7.
45. Chou WC, Wang HC, Wong FH, Ding SL, Wu PE, Shieh SY, et al. Chk2-dependent phosphorylation of XRCC1 in the DNA damage response promotes base excision repair. EMBO J 2008; 27: 3140-50.
46. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316: 1160-6.
47. Eich M, Roos WP, Nikolova T, Kaina B. Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide. Mol Cancer Ther 2013; 12: 2529-40.
48. Liang ML, Ma J, Ho M, Solomon L, Bouffet E, Rutka JT, et al. Tyrosine kinase expression in pediatric high grade astrocytoma. J Neurooncol 2008; 87: 247-53.
49. Jalali S, Chung C, Foltz W, Burrell K, Singh S, Hill R, et al. MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy. Neuro-Oncol 2014;16:868–79.
50. Birmingham A, Selfors LM, Forster T, Wrobel D, Kennedy CJ, Shanks E, et al. Statistical methods for analysis of high-throughput RNA interference screens. Nature Methods 2009; 6: 569-75.
51. Henderson MC, Gonzales IM, Arora S, Choudhary A, Trent JM, Von Hoff DD, et al. High-throughput RNAi screening identifi es a role for TNK1 in growth and survival of pancreatic cancer cells. Mol Cancer Res 2011; 9: 724-32.
52. Bax DA, Little SE, Gaspar N, Perryman L, Marshall L, Viana-Pereira M, et al. Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. PloS One 2009; 4: e5209.
53. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, et al. Glioma stem cell lines expanded in adherent culture have tumor-specifi c phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009; 4: 568-80.